Condition: Sarcoma · Solid Tumor, Adult · Solid Tumor, Childhood · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.
This description comes directly from the study's public registry record.
Megan Petrycki, RN · 410-955-0432 · mpetryc1@jhmi.edu
Tammy Scott, RN · 410-614-5990 · scottta@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Active Not Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Albert Einstein College of Medicine, Children's Hospital at Montefiore | The Bronx, New York, United States | Recruiting |
| New York Medical Center/ Maria Fareri Children's Hospital | Valhalla, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03465592